The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020crobial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Leadership Team

 

Peder M. Andersen MD,
Chief Executive Officer
Richard Forster PhD,
Chief Technical Officer 
Niels Laursen MBA,
Chief Financial Officer
Professional experience Professional experience Professional experience
  • Peder Andersen holds 1 139 905 shares through his wholly owned company Fred Management ApS

  • Chief Executive Officer at Biosergen AS since 2017

  • As CEO at Forward Pharma from 2012-2017, he was heading all development and IP activities and was instrumental in the IPO on the NY Nasdaq (USD 235m)

  • Managing director at Forward Pharma GmbH from 2009-2016

  • Vice President of clinical development at Astion Pharma from 2010-2012
  • 17 years with Glaxo (UK) in Senior Clinical Development Production and Quality Assurance roles

  • 3 tears with Fisons (UK), Senior role in Clinical Trial Supply and Quality Assurance

  • Independent Pharmaceutical Quality Assurance consultant since 1996. Key areas of expertise include Technology Transfer Strategies, Clinical Supply Planning and Delivery, Regulatory Strategy and Compliance, Good Manufacturing Practices and more
  • Currently Owner at Dwork, offering Strategic consulting and business development

  • Formerly CFO at Oncology Venture

  • CFO at Medical Prognosis Institute

  • Healthcare Innovation Manager at Blue Ocean Robotics

  • Director HR at TopoTarget A/S
Educational background Educational background Educational background
  • Doctor of Medicine (MD) from Copenhagen University
  • PhD from London University, Chemistry thesis

  • BSc (Chemistry) from London University, Imperial College
  • MBA, cand.merc from Copenhagen Business School